#MPNs,
🎉 An Oxford spin-out co-founded by our Professors Adam Mead and Beth Psaila has secured $90 million in funding to develop new therapies for myeloproliferative neoplasms (MPNs), a group of blood cancers! 🧪

🔗 https://www.imm.ox.ac.uk/news/alethio-series-a-90-million
@rdm.ox.ac.uk @medsci.ox.ac.uk
November 6, 2026 at 10:05 AM
the NCCN patient webinar covering MPNs is now available online!

www.youtube.com/watch?v=3kJM...
October 27, 2026 at 4:52 PM
Join the Canadian MPN Network for its Annual Conference - MPN: Heart, Health, and Hope.
Topics
- Cardiac Health In MPNs
- Complementary Therapies MPN-Fit Study & Nutrition
- Bone Marrow & Understanding BMB Results
Date Saturday, October 24, 2026
Time 12:30 PM EST
Register: https://ow.ly/yWVx50ZWvYV
October 23, 2026 at 10:30 PM
Join the Canadian MPN Network for its Annual Conference - MPN: Heart, Health, and Hope.
Topics
- Cardiac Health In MPNs
- Complementary Therapies MPN-Fit Study & Nutrition
- Bone Marrow & Understanding BMB Results
Date Saturday, October 24, 2026
Time 12:30 PM EST
Register: https://ow.ly/yWVx50ZWvYV
October 20, 2026 at 10:30 PM
check out this issue focused on MPNs for Seminars in Hematology that I had the chance to serve as co-editor for!

Editorial here - pubmed.ncbi.nlm.nih.gov/42887945/
October 17, 2026 at 7:03 PM
Join the Canadian MPN Network for its Annual Conference - MPN: Heart, Health, and Hope.
Topics
- Cardiac Health In MPNs
- Complementary Therapies MPN-Fit Study & Nutrition
- Bone Marrow & Understanding BMB Results
Date Saturday, October 24, 2026
Time 12:30 PM EST
Register: https://ow.ly/yWVx50ZWvYV
October 17, 2026 at 10:30 PM
Join the Canadian MPN Network for its Annual Conference - MPN: Heart, Health, and Hope.
Topics
- Cardiac Health In MPNs
- Complementary Therapies MPN-Fit Study & Nutrition
- Bone Marrow & Understanding BMB Results
Date Saturday, October 24, 2026
Time 12:30 PM EST
Register: https://ow.ly/yWVx50ZWvYV
October 15, 2026 at 10:30 PM
In this paper, the authors found that a driver mutation VAF increase of at least 10% was independently associated with poorer progression-free survival in MPNs. Serial VAF monitoring may help identify patients who need closer follow-up. Read it here: https://hsphere.pub/ppy
October 14, 2026 at 9:05 AM
Join the Canadian MPN Network for its Annual Conference - MPN: Heart, Health, and Hope.
Topics
- Cardiac Health In MPNs
- Complementary Therapies MPN-Fit Study & Nutrition
- Bone Marrow & Understanding BMB Results
Date Saturday, October 24, 2026
Time 12:30 PM EST
Register: https://ow.ly/yWVx50ZWvYV
October 12, 2026 at 10:30 PM
a comprehensive review on PIM1 in MPNs!

www.nature.com/articles/s41...
October 10, 2026 at 4:06 AM
🔴 Happening now: Complications in MPNs. #Thrombosis

Dr. Shivani Handa is discussing blood clot risks associated with myeloproliferative neoplasms (MPNs) at Blood Cancers OncTalk 2026.

💬 Join us now to hear more about it! It’s free:
give.cancergrace.org/event/blood-...

#MPNs #BloodCancer #GRACE
October 10, 2026 at 4:54 PM
🔴 How do we treat #myelofibrosis?

Dr. Shivani Handa is discussing treatment options for myelofibrosis as part of her presentation on MPNs at Blood Cancers OncTalk 2026.

💬 Join us now to hear more about it! It’s free:
give.cancergrace.org/event/blood-...

#Myelofibrosis #MPNs #BloodCancer #GRACE
October 10, 2026 at 5:12 PM
💬 Join us now to hear more about it! It’s free:
give.cancergrace.org/event/blood-...

#MPNs #BloodCancer #GRACE #OncTalk
Blood Cancers OncTalk 2026
{{MetaTags.description}}
give.cancergrace.org
October 10, 2026 at 4:54 PM
🔴 Taking the virtual stage: Dr. Shivani Handa!

Now presenting “Myeloproliferative Neoplasms (MPNs) in 2026” at Blood Cancers OncTalk.

Learn about MPN symptoms and blood clot risks, who may need treatment, available options, and newer treatment developments.+
October 10, 2026 at 4:54 PM
🔴 Our second panel’s live Q&A is underway at Blood Cancers OncTalk 2026!

Our experts are answering your questions about MPNs:
▪️ What determines someone’s risk of complications like blood clots, and how does that guide treatment?
+
October 10, 2026 at 5:28 PM
▪️ What changes in blood counts, symptoms, or test results could signal that an MPN is progressing?

💬 Join us now to hear the discussion and bring your questions! It’s free:
give.cancergrace.org/event/blood-...

#MPNs #BloodCancer #GRACE #OncTalk
Blood Cancers OncTalk 2026
{{MetaTags.description}}
give.cancergrace.org
October 10, 2026 at 5:28 PM
thanks to the NCI for inviting me to speak at the Early Drug Development Conference and highlighting our ongoing study of ASTX727 +/- iadademstat in accelerated/blast-phase MPNs!

events.cancer.gov/ctep/earlydr...
October 8, 2026 at 2:35 PM
Aae Suzuki, Liang Zhao, Chelsea Thorsheim, Brittany Weiderhold, Changsong Yang, Valerie Tutwiler, Carla Casu, Jacob W Myerson, Elizabeth O Hexner, Narla Mohandas, Vladimir R Muzykantov, Rustem I Litvinov, Chandrasekaran Nagaswami, Rebecca A Risman, Peng Ji, Timothy J Stalker, Aaron R Goldman, et al.
Aberrant erythrocyte rigidity in JAK2<sup>V617F</sup> myeloproliferative neoplasms underlies concurrent thrombosis and hemorrhage
Thrombotic events are the leading cause of death in myeloproliferative neoplasms (MPNs) driven by the JAK2 Val^(617)→Phe (JAK2V617F) mutation. We investigated how JAK2V617F alters hemostasis and thrombosis in humans and in lineage-specific knockin mice to test whether red blood cell (RBC) mechanics contribute directly to clot pathology. Jak2^(F/+)Vav-Cre knockin mice form structurally aberrant clots characterized by extended clot formation times and unstable hemostatic plug formation....
www.science.org
October 7, 2026 at 10:00 PM
Writing a review is more than collecting papers. It’s about finding a clear story in a fast-moving field and deciding what matters most,.
For this review on TP53 mutations in MPNs, collaboration across France and Brazil a brought together different perspectives https://hsphere.pub/11ca11
October 2, 2026 at 9:03 AM
[ Identifiers ] carry 20% of your AI-readiness score. Missing GTINs, mismatched MPNs, absent brand names. Channels can’t match your product to their graph without them. Free scan: https://audit.flintmere.com?utm_source=x&utm_medium=organic&utm_campaign=identifiers-pillar
October 1, 2026 at 10:00 AM
thanks to the NCCN for letting me participate as a panelist in a patient webinar all about MPNs!

www.nccn.org/patientresou...
September 24, 2026 at 7:43 PM
For #BloodCancerAwarenessMonth, we’re revisiting #MRCWIMM #bloodcancer research every Monday.

This week: Prof Beth Psaila and colleagues’ work on personalised CAR T cell therapy for myeloproliferative neoplasms.

@rdm.ox.ac.uk @medsci.ox.ac.uk #AcademicSky 🧪
New personalised therapy targets chronic blood cancer
A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving hea...
www.imm.ox.ac.uk
September 21, 2026 at 8:37 AM
Today is #WorldMPNDay! 🧡
MPNs are blood cancers affecting bone marrow. Today we encourage those living with MPNs to share their experiences.
Your voice matters! #MPN #BCAM @GMPNAN
September 14, 2026 at 9:00 AM
Today is MPN Awareness Day ❤️

MPNs are a group of rare blood cancers that affect how your body makes blood cells.

There are 3 main types: polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis (MF).

Around 4,180 people are diagnosed in the UK each year.
September 12, 2026 at 8:20 AM